ATLANTA, GA—Ninerafaxstat (Imbria Pharmaceuticals), a novel drug targeted at patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM), is safe and well tolerated, according to data ...

Future Cardiol. 2013;9(5):697-709. It is extremely important to detect the presence and severity of LVOT obstruction from physical examination, as well as 2D and Doppler echocardiography. The LVOT ...

Hypertrophic cardiomyopathy (HCM) is a genetic disease of the heart. Not everyone with the disease will experience symptoms, but early detection is important. Share on Pinterest izusek/Getty Images ...

Hypertrophic cardiomyopathy (HCM) is a genetic condition in which the heart muscle thickens abnormally, increasing ones risk of several serious heart complications. The muscle thickening disrupts ...

LISBON, Portugal—Patients with obstructive hypertrophic cardiomyopathy (HCM) treated with aficamten (Cytokinetics), an inhibitor of cardiac myosin, had statistically significant and clinically ...

MINNEAPOLIS — Readouts of data on an experimental drug for hypertrophic cardiomyopathies showed the agent appeared safe and effective in long-term treatment and can significantly improve exercise ...

Most people with HCM can participate in mild- to moderate-intensity exercise safely. When it comes to vigorous exercise and competitive sports, there may be a need for additional guidance from your ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...

The hypertrophic cardiomyopathies include several diseases with different etiologies, all of which are characterized by abnormal thickening of the myocardium, most commonly in the interventricular ...

Hypertrophic cardiomyopathy (HCM) affects one in 500 people in the general population. In most cases, HCM is caused by genetic mutations. Doctors usually discover HCM during cardiac testing (an ...